Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with Salvage Radiation Therapy in Recurrent Prostate Cancer
NCT02203695Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02203695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203695.